18FDG PET/CT and CA 15-3 in the early diagnosis of recurrent breast cancer;Apports de la TEP-TDM au18FDG couplée au CA 15-3 dans le diagnostic précoce des récidives du cancer du sein

Medecine Nucleaire

Volumn 30, Issue 4, 2006, Pages 209-216

  Guillemard, Sophie ^a,c   Eberle Pouzeratte M C ^a   Lamy, P J ^a   Romieu, G ^a   Rossi, M ^b   Artus, J C ^a  

^a CRLCC Montpellier   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

18FDG; Breast cancer; CA 15 3; PET CT; Recurrences

Indexed keywords

CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PHOTON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RECURRENT CANCER; SENSITIVITY ANALYSIS;

EID: 33744964400     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Cin Oncol 2001;20:620-3
2. Pouillard P. Les causes d'échecs de la chimiothérapie. Les mécanismes de résistance. Livret « cancer du sein métastatique. Chimiothérapie de première ligne ». Bristol-Meyers Squibb 1997.
3. Basuyau JP, Brunette P, Charrot P. CA 15-3 et diagnostic précoce de récidive dans les cancers du sein. Bull Cancer 1993;80:213-8
4. Basuyau JP, Blanc-Vincent MP, Bidart JM. Standards, Options et Recommandations (SOR): marqueurs tumoraux sériques du cancer du sein. Bull Cancer 2000;87:723-37
5. Jäger W, Lang W Erlangen. Tumor marker study on breast cancer. Eur J Obstet Gynecol Reprod Biol 1993;85:1-2
6. Kovner F, Merimsky O, Hareuveni M. Treatment of disease negative but mucine-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomised trial. Cancer Chemother Pharmacol 1994;35:80-3
7. Nicolini A, Anselmi L, Mechelassi C. Prolonged survival by « early » salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106-11
8. Gallowitsch KG, Igerc I, Mikosch P. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. invest Radial 2003;38:250-6
9. Zangheri B, Mess a C, Picchio M. PET/CT and breast cancer. Eu J Nucl Med 2004;31:135-43
10. Israel O, Mor M, Guralnik L. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nul Med 2004;45:2045-51
11. Agence national d'accréditation et d'évaluation en santé (ANAES). Marqueurs sériques dans les cancers du sein et les cancers colorectaux. Recommandations et Références médicales. Sept 1997
12. De La Lande B, Hacene K, Floiras JL. Prognostic value of CA 15-3 kinetics for metastatic breast cancer. The International Journal of Biological Markers 2002;17:231-8
13. De La Lande B. Place actuelle des dosages du CA 15-3 dans le cancer du sein. Immuno-analyse et Biologie spécialisée 2004;19:274-8
14. Molina R, Zanon G, Filella X. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Can Res Treat 1995;36:41-8
15. Avril N, Rose CA, Schelling M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-502
16. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based Positron Emission Tomography. Clin Breast Can 2001;2:229-34
17. Suarez M, Pérez-Castejon J, Jimenez A. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113-21
18. Liu CS, Shen YY, Lin CC. Clinical impact of [18F] FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002;32:244-7
19. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PETfor the evaluation of breast cancer recurrence and metastases. Breast Cancer Research and Treatment 2005;90:105-12
20. Standards, Options et Recommandations. Cancers du sein infiltrants non métastatiques (2e édition, mise à jour). Editions John Libbey Eurotext, 2001